Oragenics Inc is a biotechnology company focused on the development of innovative solutions for infectious diseases and oral health. The company is primarily engaged in creating novel antibiotics and therapeutics, particularly against multi-drug resistant pathogens, as well as products aimed at enhancing oral health through advanced microbial therapies. Oragenics leverages its proprietary technologies and research capabilities to address significant medical needs, with a mission to improve patient outcomes and combat rising antibiotic resistance through targeted and effective treatment options. Read More
Wondering how the US markets performed one hour before the close of the markets on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
Let's have a look at what is happening on the US markets before the opening bell on Monday. Below you can find the top gainers and losers in today's pre-market session.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Wednesday. Below you can find the top gainers and losers in today's session.
Oragenics (NYSE American: OGEN) announced that its board has approved a 1-for-30 reverse stock split of its common shares, effective June 3, 2025. The move consolidates every 30 shares into one and aims to boost the company’s share price and appeal to long-term investors. Shares will begin trading on a split-adjusted basis under the existing symbol “OGEN” with a new CUSIP number. CEO Janet Huffman stated the action aligns with Oragenics’ strategy to enhance its capital markets profile while advancing treatments for brain-related health conditions.
Oragenics (NYSE American: OGEN) a biotechnology company developing intranasal therapies for brain-related disorders, announced it has received approval from Australia’s Human Research Ethics Committee (“HREC”) to begin a Phase II clinical trial of ONP-002, its proprietary neuroprotective therapy for mild traumatic brain injury (mTBI), or concussion. The clearance enables the company to initiate patient enrollment as early as Q2 2025 at Level 1 trauma emergency departments, where concussed patients are often treated. ONP-002, a non-invasive intranasal formulation, has demonstrated safety in Phase I and efficacy in preclinical models by reducing inflammation, oxidative stress and brain swelling. CEO Janet Huffman said the approval marks a key step toward expanding the ONP-002 program internationally, with enrollment sites also under consideration in New Zealand.
Oragenics (NYSE American: OGEN) will host a management update webinar on Tuesday, May 20, 2025, at 4:00 p.m. ET to discuss the unmet medical need in concussion treatment and highlight its lead candidate, ONP-002. The intranasal therapy is currently in a Phase IIa trial for mild traumatic brain injury and has shown promising preclinical results in reducing brain inflammation and swelling. Presenters will include CEO Janet Huffman, CMO Dr. James Kelly, and Chief Clinical Officer Dr. Frank Peacock, a national emergency medicine expert.
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Oragenics (NYSE American: OGEN) announced the submission of its Phase II clinical trial protocol to New Zealand’s Health and Disability Ethics Committee, advancing plans to evaluate ONP-002, its intranasal neurosteroid therapy for mild traumatic brain injury. If approved, patient enrollment will begin at Christchurch Hospital, one of Australasia’s busiest emergency care centers. The company aims to expand its clinical reach across Australia and New Zealand, addressing a major unmet need for concussion treatment.
Oragenics (NYSE American: OGEN), a biotechnology company developing intranasal therapies for brain-related disorders, announced that Chief Medical Officer Dr. James Kelly participated in a panel at the 3rd Nasal Formulation & Delivery Summit held April 1–3 in Boston. Dr. Kelly discussed advancements in intranasal drug delivery, its benefits for neurological treatment, and the company’s progress with ONP-002, a neurosteroid aimed at improving concussion outcomes through rapid, targeted brain delivery.
Oragenics (NYSE American: OGEN) reported significant strategic progress in Q1 2025 as it advances ONP-002, its intranasal concussion therapy, toward clinical Phase IIa trials in Australia. The company secured a partnership with BRAINBox Solutions to integrate diagnostic biomarkers with its treatment platform and raised approximately $5 million through a mix of equity and non-dilutive debt. Oragenics also finalized regulatory submissions and drug production, with first patient enrollment expected in Q2. With no FDA-approved treatments for concussion, ONP-002 is positioned as a potential first-in-class therapy addressing a major unmet need.
Oragenics (NYSE American: OGEN) announced the filing of its Annual Report on Form 10-K for the year ended Dec. 31, 2024, with the U.S. Securities and Exchange Commission on March 14, 2025. The company’s audited financial statements received an unqualified audit opinion, though an explanatory paragraph raised concerns about its ability to continue as a going concern. Oragenics remains focused on advancing its pipeline of treatments for concussion and brain-related health conditions while pursuing strategic opportunities to ensure long-term growth. Further details are available in Footnote 1 of the financial statements.
